Vanda Salutari

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 09, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: February 10, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology

Published: February 02, 2026

Clinical and molecular heterogeneity in advanced-stage POLE-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations.

Clinical and molecular heterogeneity in advanced-stage POLE-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations.

Journal: Frontiers in oncology

Published: January 31, 2026

Corneal Toxicity of Mirvetuximab Soravtansine: Multimodal Imaging Features and Implications for Ophthalmologic Management.

Corneal Toxicity of Mirvetuximab Soravtansine: Multimodal Imaging Features and Implications for Ophthalmologic Management.

Journal: Diagnostics (Basel, Switzerland)

Published: January 06, 2026

Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.

Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.

Journal: Tumori

Published: December 15, 2025

Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review.

Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 12, 2025

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 17, 2025

Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer.

Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer.

Journal: Targeted oncology

Published: October 06, 2025

Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy.

Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy.

Journal: Critical reviews in oncology/hematology

Published: September 30, 2025

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 09, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026